search

Active clinical trials for "Leukemia, Lymphocytic, Chronic, B-Cell"

Results 361-370 of 1487

Understanding Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.

Recruiting4 enrollment criteria

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens...

Chronic Lymphocytic LeukemiaRelapse Leukemia1 more

Observational study aimed at describing the characteristics and outcome of CLL patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in Italy in a period of time ranging from the start of the Venetoclax Named Patient Program (March 2016) until October 31st, 2021.

Recruiting4 enrollment criteria

Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

LeukemiaLymphocytic2 more

This is a Phase I, open-label, single-arm, single center study to assess the safety and efficacy of JWCAR029 in subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Not yet recruiting23 enrollment criteria

Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia

Pneumococcal InfectionsChronic Lymphocytic Leukemia3 more

In this study the antibody response after vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23) in adults with chronic lymphocytic leukemia will be investigated.

Recruiting4 enrollment criteria

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen...

Acute Lymphoblastic Leukemiain Relapse5 more

This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

Not yet recruiting30 enrollment criteria

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Autoimmune Hemolytic AnemiaChronic Lymphocytic Leukemia2 more

This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.

Not yet recruiting10 enrollment criteria

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use

Recruiting4 enrollment criteria

A Case Crossover Study of Intermittent Fasting in CLL/SLL

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

The purpose of this study is to compare the 16/8 intermittent fasting method with the 5:2 Method in a subset of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma at BC Cancer- Victoria. The purpose is to find out which is the preferred method by patients and which has the greatest effect on: cancer cells (lymphyocyte count), metabolism (autophagy activation), inflammation (CRP), gut microbiome (metabolomic analysis). Participants will have already completed our previous trial, "Intermittent Fasting in CLL/SLL" (ClinicalTrials.gov Identifier: NCT04626843) where they followed the 16/8 Fasting Method followed by a minimum of a 3 months washout period, and will now follow the 5:2 Method for 90 days. The same samples and outcome measures will be collected in order to directly compare the two diets in the same patient cohort.

Active15 enrollment criteria

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma1 more

This study aims to evaluate the long-term efficacy of BTK inhibitor Zanubrutinib monotherapy , sequential Zanubrutinib combined (Fludarabine, cyclophosphamide and rituximab /bendamustine and rituximab)FCR/BR regimen by a limited period of treatment for the newly diagnosed Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The investigators propose this combination will improve the MRD negative rate of patients with CR/CRi after treatment was significantly higher than that of FCR chemotherapy can be a time-limited regimen which will reduce the life-time therapy and benefit the patients.

Not yet recruiting35 enrollment criteria

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients,...

Body Mass Index 25 or GreaterBRCA1 Gene Mutation9 more

This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients, chronic lymphocytic leukemia (CLL) survivors or family members of cancer survivors who are at high risk for cancer. Increasing exercise and eating healthy foods may help reduce the risk of cancer. Studying how well different types of interventions work in motivating cancer survivors or high-risk family members to increase exercise and healthy food choices may help doctors plan the most effective motivational program for cancer prevention.

Active13 enrollment criteria
1...363738...149

Need Help? Contact our team!


We'll reach out to this number within 24 hrs